Madam Speaker, there are two issues that I would like to ask the member to comment on.
One is the fact that at the committee stage, Canadians will not be able to submit written submissions to the committee for consideration. Does the member agree with that? Why would we close opportunities for Canadians to express their points of view on this important trade deal?
Second is the issue of CETA's implications for pharmacare costs. The trade deal will have a huge implications for our pharmacare costs with respect to patents. That will have a huge impact on us. Already, in terms of health care costs, we will be dealing with a $36 billion cut as the hangover from the Harper administration, which the current government is carrying over. How would we handle the impacts on health care costs across the country vis-à-vis patents on pharmacare?